PPIDT00263
Drug Information
| Name | Dinutuximab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB09077 |
| Type | biotech |
| Indication | Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution, concentrate | Intravenous |
4.5 mg/ml
|
| Injection, solution, concentrate | Intravenous; Parenteral |
4.5 MG/ML
|
| Injection | Intravenous |
3.5 mg/1mL
|
| Injection, solution, concentrate | Intravenous |
3.5 MG/ML
|
| Solution | Intravenous |
3.5 mg / mL
|
Target Information
| Role | Uniprot_ID | Gene_Name | Entity_Name | Organism | Actions | Internal link |
|---|---|---|---|---|---|---|
| No target records. | ||||||